U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H56N4O10
Molecular Weight 824.9594
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VINCRISTINE

SMILES

CC[C@@]1(C[C@@]2([H])C[C@](c3cc4c(cc3OC)N(C=O)[C@]5([H])[C@@]64CCN7CC=C[C@](CC)([C@@]67[H])[C@]([H])([C@@]5(C(=O)OC)O)OC(=O)C)(c8c(CCN(C2)C1)c9ccccc9[nH]8)C(=O)OC)O

InChI

InChIKey=OGWKCGZFUXNPDA-CFWMRBGOSA-N
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/vincristine.html

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT.

Originator

Curator's Comment:: # Dr. James. Armstrong of Eli Lilly and Company

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P07437
Gene ID: 203068.0
Gene Symbol: TUBB
Target Organism: Homo sapiens (Human)
1.6 µM [IC50]
0.17 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Marqibo

Approved Use

Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

Launch Date

1.34438401E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1220 ng/mL
2.25 mg/m² steady-state, intravenous
dose: 2.25 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VINCRISTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14566 ng × h/mL
2.25 mg/m² steady-state, intravenous
dose: 2.25 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VINCRISTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
25%
VINCRISTINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.25 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 18
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 18
Sources: Page: p.1,6
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
DLT: Motor polyneuropathy, Seizure...
Dose limiting toxicities:
Motor polyneuropathy (grade 3, 14.3%)
Seizure (grade 4, 14.3%)
Hepatotoxicity (grade 4, 14.3%)
Sources: Page: p.1,6
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (grade 4, 33.3%)
Obstipation
Myalgia (grade 3, 33.3%)
Sources: Page: p.701
2.4 mg/m2 3 times / week multiple, intravenous
MTD
Dose: 2.4 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 3 times / week
Sources: Page: p.704
unhealthy, 32-83
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 6
Sources: Page: p.704
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Disc. AE: Peripheral neuropathy, Tumor lysis syndrome...
AEs leading to
discontinuation/dose reduction:
Peripheral neuropathy (10%)
Tumor lysis syndrome (2%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Motor polyneuropathy grade 3, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Hepatotoxicity grade 4, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Seizure grade 4, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Obstipation DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Myalgia grade 3, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Neutropenia grade 4, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Thrombocytopenia grade 4, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Peripheral neuropathy 10%
Disc. AE
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Tumor lysis syndrome 2%
Disc. AE
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
yes
yes
yes (co-administration study)
Comment: the total area under the plasma concentration-time curve was 43% smaller in patients who were receiving carbamazepine or phenytoin than in the control group; the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort)
Page: 31.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Vincristine-induced myocardial infarction.
1975 Dec
Vincristine-induced autonomic neuropathy.
1975 Jul 26
[Superiority of intrafascicular neurography over conventional nerve conduction studies in evaluating axonal degeneration].
1999 Apr
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
1999 Apr 29
Pain related behaviour during vincristine-induced neuropathy in rats.
1999 Apr 6
Vincristine revisited.
1999 Feb
Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.
1999 Jul
Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis.
1999 Mar
[Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].
1999 May
Low-dose vincristine-associated bilateral vocal cord paralysis.
1999 Oct
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
1999 Oct
Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol--in vitro explant study.
1999 Oct 22
Clinical and electrophysiological studies in vincristine induced neuropathy.
1999 Sep
Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells.
1999 Sep
Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
2000
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
2000 Aug
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
2000 Mar
[Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis].
2000 Nov
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.
2000 Oct
Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat.
2000 Sep 4
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
2001
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
2001 Apr
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.
2001 Aug 3
Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.
2001 Feb 16
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
2001 Jul
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.
2001 Mar
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
2001 Mar
Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport.
2001 May 11
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
2001 May 18
Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity.
2001 May 18
Ischemic heart disease associated with vincristine and doxorubicin chemotherapy.
2001 Nov
Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.
2001 Oct 15
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.
2001 Sep
Massive cell death of cerebellar granule neurons accompanied with caspase-3-like protease activation and subsequent motor discoordination after intracerebroventricular injection of vincristine in mice.
2002
Effect of thiopental, propofol, and etomidate on vincristine toxicity in PC12 cells.
2002
Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.
2002 Apr
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
2002 Apr 15
Identification and characterization of the canine multidrug resistance-associated protein.
2002 Dec
Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity.
2002 Dec
Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.
2002 Dec 15
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
2002 May 1
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
2002 Nov-Dec
Vincristine-itraconazole interaction: cause for increasing concern.
2002 Oct
Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat.
2003 Aug 1
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
2003 Jul 15
Bilateral hearing loss during vincristine therapy: a case report.
2003 Jun
The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.
2003 May 16
Functional expression of the multidrug resistance protein 1 in microglia.
2003 Oct
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: For Intravenous Use Only. Fatal if Given by Other Routes.
Marqibo is liposome-encapsulated vincristine. 2.25 mg/m2 intravenously over 1 hour once every 7 days.
Route of Administration: Intravenous
In Vitro Use Guide
Treatment of macrophage monolayers for 24 h with vincristine (10(-5)-10(-7) M) inhibited the antibody dependent cellular cytotoxicity (ADCC) by PMA stimulated rat macrophages.
Name Type Language
VINCRISTINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
(+)-VINCRISTINE
Common Name English
22-OXOVINCALEUKOBLASTINE
Common Name English
VINCALEUKOBLASTINE, 22-OXO-
Common Name English
ONCOTCS
Brand Name English
VINCRISTINE [WHO-DD]
Common Name English
VINCRISTINE [VANDF]
Common Name English
TECNOCRIS
Brand Name English
VINCRISTINE [MI]
Common Name English
VINCRISTINE [HSDB]
Common Name English
VINKRISTIN
Common Name English
VCR
Common Name English
LEUROCRISTINE
Common Name English
LEUCRISTINE
Common Name English
VINCRISTINE [INN]
Common Name English
VINCRISTIN
Common Name English
Classification Tree Code System Code
WHO-VATC QL01CA02
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
LIVERTOX 1030
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
NCI_THESAURUS C932
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
WHO-ATC L01CA02
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
NDF-RT N0000007780
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
NDF-RT N0000007780
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
NCI_THESAURUS C67422
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
NDF-RT N0000175612
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
Code System Code Type Description
DRUG BANK
DB00541
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL90555
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
EVMPD
SUB00059MIG
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
MERCK INDEX
M11453
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY Merck Index
EPA CompTox
57-22-7
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
INN
1440
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
DRUG CENTRAL
2825
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-318-1
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
NCI_THESAURUS
C933
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
RXCUI
11202
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY RxNorm
PUBCHEM
5388993
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
FDA UNII
5J49Q6B70F
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
CAS
57-22-7
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
WIKIPEDIA
VINCRISTINE
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
MESH
D014750
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
IUPHAR
6785
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
HSDB
3199
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY
LACTMED
Vincristine
Created by admin on Sat Jun 26 06:43:24 UTC 2021 , Edited by admin on Sat Jun 26 06:43:24 UTC 2021
PRIMARY